Thorsten Walles

Thorsten Walles

Auto-generated profile, based on publicly available information

Thorsten Walles

Department of Cardiothoracic Surgery, University Hospital of Wuerzburg, 97080 Wuerzburg, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2016 in Genes
Verified
Journal Article
Open access
PDF file
MKMeik Kunz
Meik Kunz
BWBeat Wolf
Beat Wolf
HSHarald Schulze
Harald Schulze
DADavid Atlan
David Atlan
TWThorsten Walles
Thorsten Walles
Thomas DandekarThomas Dandekar
Thomas Dandekar
Lung cancer is currently the leading cause of cancer related mortality due to late diagnosis and limited treatment intervention. Non-coding RNAs are not translated into proteins and have emerged as fundamental regulators of gene expression. Recent studies reported that microRNAs and long non-coding RNAs are involved in lung cancer development and progression. Moreover, they appear as new promising non-invasive biomarkers for early lung cancer diagnosis. Here, we highlight their potential as biomarker in lung cancer and present how bioinformatics can contribute to the development of non-invasive diagnostic tools. For this, we discuss several bioinformatics algorithms and software tools for a comprehensive understanding and functional characterization of microRNAs and long non-coding RNAs.

30 November 2015 in Trials
Verified
Journal Article
Open access
PDF file
JNJens Neudecker
Jens Neudecker
UMUwe Malzahn
Uwe Malzahn
PHPeter Heuschmann
Peter Heuschmann
UBUwe Behrens
Uwe Behrens
TWThorsten Walles
Thorsten Walles
For the surgical treatment of recurrent primary spontaneous pneumothoraces (rPSP) different operative therapies are applied to achieve permanent freedom from recurrence. This multicenter clinical trial evaluates the long-term results of two commonly applied surgical techniques for the treatment of rPSP. Based on the inclusion and exclusion criteria, and after obtaining the patients’ informed consent, participants are randomized into the two surgical treatment arms: pulmonary wedge resection plus parietal pleurectomy (WRPP) or parietal pleurectomy alone (PP). Consecutively, all study participants will be followed up for two years to evaluate the surgical long-term effect. The primary efficacy endpoint is the recurrence rate of pneumothorax within 24 months after surgery. The calculated sample size is 360 patients (n = 180 per treatment arm) to prove superiority of one of the two treatments. So far, 22 surgical sites have submitted their declaration of commitment, giving the estimated number of participating patients. A prospective randomized clinical trial has been started to compare two established surgical therapies to evaluate the long-term results regarding recurrence rates. Furthermore, cost of treatment, and influence on the perioperative morbidity and mortality as well as on quality of life are analyzed. If the study reveals equivalence for both surgical techniques, unnecessary pulmonary resections could be avoided. ClinicalTrials gov: NCT01855464 , 06.05 2013.

7 November 2015 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
TWThorsten Walles
Thorsten Walles

8 June 2016 in Zeitschrift für Herz-,Thorax- und Gefäßchirurgie
Verified
Journal Article
Closed access
PDF file
GSG. Somuncuoglu
G. Somuncuoglu
THT. Hoppert
T. Hoppert
TWT. Walles
T. Walles